SelankvsThymulin

Selank is a synthetic heptapeptide based on the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), with a stabilizing Pro-Gly-Pro extension at the C-terminus that dramatically increases its resistance to aminopeptidase degradation. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, it was designed to combine the immune-enhancing effects of tuftsin with anxiolytic and nootropic properties.

The anxiolytic mechanism involves modulation of GABAergic neurotransmission. Selank acts as an allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of GABA in anxiety-related brain regions including the amygdala, hippocampus, and prefrontal cortex. This produces a benzodiazepine-like anxiolytic effect without the sedation, cognitive impairment, or addiction potential associated with benzodiazepines — because Selank modulates rather than directly activates the receptor. Additionally, Selank stabilizes enkephalins (endogenous opioid pentapeptides) by inhibiting enkephalin-degrading enzymes (aminopeptidases and enkephalinase/neprilysin), prolonging their mood-regulating and anxiolytic signaling.

The nootropic effects are mediated through neurotrophic factor upregulation. Selank increases expression of brain-derived neurotrophic factor (BDNF) in the hippocampus and prefrontal cortex, promoting dendritic branching, synaptic plasticity, and long-term potentiation — the cellular mechanisms underlying memory formation and cognitive flexibility. It also modulates serotonergic (5-HT) metabolism, altering the balance between serotonin and its metabolite 5-HIAA in key brain regions. The immunomodulatory component derives from the tuftsin core: tuftsin naturally activates monocytes and macrophages through specific receptors, enhancing phagocytic activity and modulating IL-6, TNF-α, and other cytokine production. This immune regulation occurs at sub-anxiolytic doses, suggesting it is an independent pharmacological effect. The combined anxiolytic, cognitive-enhancing, and immunomodulatory profile is unique among available peptides.

Thymulin (also known as facteur thymique sérique, FTS) is a nonapeptide (Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) that is unique among thymic hormones in requiring a zinc ion for biological activity. The zinc ion is coordinated by the asparagine (position 9), serine (position 4), and the N-terminal glutamic acid, creating a metallopeptide complex where the zinc is essential for the correct three-dimensional conformation needed for receptor binding. Without zinc, thymulin is biologically inactive — this zinc dependency has important implications for immune function in zinc-deficient individuals.

Thymulin is produced exclusively by thymic epithelial cells and is the only thymic hormone that is truly thymus-specific — its serum levels become undetectable after thymectomy (surgical thymus removal). It binds to high-affinity receptors on T-cell precursors (thymocytes) and mature T cells, promoting several key aspects of T-cell biology. It induces the expression of T-cell differentiation markers (CD2, CD3, CD4, CD8), driving immature thymocytes through the stages of T-cell maturation. It enhances the cytotoxic function of CD8+ T cells and the helper function of CD4+ T cells. It modulates the balance between T-helper and T-suppressor (regulatory) cell populations, promoting appropriate immune regulation.

Thymulin also modulates cytokine production — it promotes IL-2 secretion (essential for T-cell proliferation and the generation of effector T cells), enhances IFN-γ production (important for Th1 cellular immunity), and influences the balance of pro-inflammatory versus anti-inflammatory cytokines. Serum thymulin levels peak around puberty and decline progressively with age, becoming virtually undetectable by age 60 — mirroring the age-related involution of the thymus gland. This decline correlates closely with immunosenescence markers: reduced naive T-cell output, skewed CD4/CD8 ratios, impaired vaccine responses, and increased susceptibility to infections and cancer. Zinc supplementation alone can partially restore thymulin activity in zinc-deficient elderly individuals, highlighting the clinical importance of the zinc-thymulin interaction.